Trials
Search / Trial NCT00001497

Assessment of Attentional Functioning in Children With HIV-1 Infection

Launched by NATIONAL CANCER INSTITUTE (NCI) · Dec 9, 2002

Apply for Trial

Trial Information

Current as of March 15, 2025

Completed

Keywords

Brain Imaging Encephalopathy Hyperactivity Neuroimmunology Reaction Time Tasks

ClinConnect Summary

Children with symptomatic HIV-1 (Human Immunodeficiency Virus) infection are at increased risk for developing severely disabling neurological and neuropsychological deficits. HIV-1 related CNS (Central Nervous System) disease is a clinical syndrome, manifested by varying and sometimes discordant degrees of cognitive, motor and behavioral impairment. A continuum of clinical presentations attributed to the effects of HIV-1 infection on the CNS, ranging from apparently normal development, decreases in the rate of new learning to the loss of acquired skills have been observed. Two domains of ps...

Gender

ALL

Eligibility criteria

  • • Children and adolescents with HIV infection ages 5-18.
  • • Have to be on another treatment protocol at the Division of Clinical Sciences, NCI.
  • • No children with non-HIV associated CNS compromise, such as for example resulting from head trauma, or genetic factors.
  • • No children with uncorrectable (20/20) vision.

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials